Bevacizumab dose adjustment for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adjusting the dose of bevacizumab based on your blood levels can improve first-line treatment for metastatic colorectal cancer that can't be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic colorectal cancer that cannot be fully removed by surgery.
- You have not had treatment for metastatic cancer before (or if you had chemotherapy after surgery, it ended more than 6 months ago for a single drug, or more than 12 months ago for a combination).
- Your overall health allows you to be up and about (ECOG score 0-2).
- Your blood tests show adequate kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
This trial tests whether adding a drug called bevacizumab (which helps stop blood vessel growth to tumors) to a combination of two chemotherapy drugs (oxaliplatin and TAS-102) can help people with advanced colorectal cancer. It is for people who have not yet received treatment for their advanced cancer.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.